drug

rese-cel

1 story · latest Aug 13, 2026

Status: Investigational
Code: CABA-201
Trials: 3 registered trials in coverage

Relationships

Developed by Cabaletta Bio

Also known as

resecabtagene autoleucel

Timeline

Cabaletta reports Q2 2026 results, reaffirms mid-2027 myositis data and 2H27 BLA plan

Aug 13Quarterly updateCabaletta Bio

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.